Twelve versus 36 months of adjuvant imatinib (IM) as treatment of operable GIST with a high risk of recurrence: Final results of a randomized trial (SSGXVIII/AIO).

被引：1
|
作者：
Joensuu, H.
Eriksson, M.
Hatrmann, J.
Hall, K. Sundby
Schutte, J.
Reichardt, A.
Schlemmer, M.
Wardelmann, E.
Ramadori, G.
Al-Batran, S.
Nilsson, B. E.
Monge, O.
Kallio, R.
Sarlomo-Rikala, M.
Bono, P.
Leinonen, M.
Hohenberger, P.
Alvegard, T.
Reichardt, P.
机构：
[1] Univ Helsinki, Cent Hosp, Helsinki, Finland
[2] Univ Lund Hosp, S-22185 Lund, Sweden
[3] Univ Klinikum Schleswig Holstein, Kiel, Germany
[4] Oslo Univ Hosp, Oslo, Norway
[5] Marien Hosp Duesseldorf, Dusseldorf, Germany
[6] HELIOS Klinikum Berlin Buch, Sarcoma Ctr Berlin Brandenburg, Berlin, Germany
[7] Univ Munich, Univ Hosp Grosshadern, Munich, Germany
[8] Univ Bonn, Bonn, Germany
[9] Univ Gottingen, D-37073 Gottingen, Germany
[10] Krankenhaus NW Frankfurt, Frankfurt, Germany
[11] Sahlgrens Univ Hosp, Gothenburg, Sweden
[12] Haukeland Hosp, Oslo, Norway
[13] Oulu Univ Hosp, Oulu, Finland
[14] Helsinki Univ Hosp, Helsinki, Finland
[15] 4Pharma, Turku, Finland
[16] Univ Klinikum Mannheim, Mannheim, Germany
[17] Lund Univ, Lund, Sweden
[18] HELIOS Klinikum Bad Saarow, Sarcoma Ctr Berlin Brandenburg, Bad Saarow Pieskow, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA1
引用
收藏
页数：1
相关论文
共 50 条
  • [31] High-risk prostate cancer treated with pelvic radiotherapy and 36 versus 18 months of androgen blockade: Results of a phase III randomized study
    Nabid, Abdenour
    Carrier, Nathalie
    Martin, Andre-Guy
    Bahary, Jean-Paul
    Souhami, Luis
    Duclos, Marie
    Vincent, Francois
    Vass, Sylvie
    Bahoric, Boris
    Archambault, Robert
    Lemaire, Celine
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [32] Survival update from a multicenter, randomized, phase III trial of vitespen versus observation as adjuvant therapy for renal cell carcinoma in patients at high risk of recurrence
    Wood, C. G.
    Srivastava, P.
    Lacombe, L.
    Gorelov, A. I.
    Gorelov, S.
    Mulders, P.
    Zielinski, H.
    Teofilovici, F.
    Isakov, L.
    Escudier, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [33] Interruption of Imatinib (IM) in responding patients after one year treatment does not influence overall survival of patients with advanced GIST: Updated results of the French Sarcoma Group randomized phase IIIBFR14 trial
    Le Cesne, A.
    Rav-Coquard, I.
    Bul, B.
    Duffaud, F.
    Deligny, N.
    Cupissol, D.
    Bay, J. O.
    Perol, C.
    Delbaldo, C.
    Blay, J. Y.
    EJC SUPPLEMENTS, 2005, 3 (02): : 202 - 202
  • [34] Does interruption of imatinib (IM) in responding GIST patients after one year of treatment influence the secondary resistance to IM after its reintroduction? Updated results of the prospective French Sarcoma Group randomized phase III trial on long term survival
    Perol, D.
    Domont, J.
    Ray-Coquard, I. L.
    Bui, B. N.
    Rios, M.
    Duffaud, F.
    Bertucci, F.
    Moneron, C.
    Chabaud, S.
    Le Cesne, A.
    Blay, J. Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [35] Adjuvant everolimus in high-risk diffuse large B-cell lymphoma: final results from the PILLAR-2 randomized phase III trial
    Witzig, T. E.
    Tobinai, K.
    Rigacci, L.
    Ikeda, T.
    Vanazzi, A.
    Hino, M.
    Shi, Y.
    Mayer, J.
    Costa, L. J.
    Bermudez Silva, C. D.
    Zhu, J.
    Belada, D.
    Bouabdallah, K.
    Kattan, J. G.
    Kuruvilla, J.
    Kim, W. S.
    Larouche, J-F
    Ogura, M.
    Ozcan, M.
    Fayad, L.
    Wu, C.
    Fan, J.
    Louveau, A-L
    Voi, M.
    Cavalli, F.
    ANNALS OF ONCOLOGY, 2018, 29 (03) : 707 - 714
  • [36] Final results of the ACTS-CC 02 trial: A randomized phase III trial of S-1/oxaliplatin (SOX) versus UFT/leucovorin as adjuvant chemotherapy for high-risk stage III colon cancer.
    Tomita, Naohiro
    Sasaki, Shin
    Kusumoto, Tetsuya
    Watanabe, Jun
    Sakamoto, Yoshiyuki
    Yoshida, Kazuhiro
    Maeda Atsuyuki
    Teshima, Jin
    Yokota, Mitsuru
    Tanaka, Chihiro
    Yamauchi, Junichiro
    Uetake, Hiroyuki
    Itabashi, Michio
    Takahashi, Keiichi
    Baba, Hideo
    Kotake, Kenjiro
    Boku, Narikazu
    Aiba, Keisuke
    Morita, Satoshi
    Sugihara, Kenichi
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [37] Adjuvant imatinib mesylate in patients with primary high risk gastrointestinal stromal tumor (GIST) following complete resection: Safety results from the US Intergroup Phase II trial ACOSOG Z9000.
    Dematteo, RP
    Antonescu, CR
    Chadaram, V
    You, YN
    McCall, L
    Maki, R
    Murgo, A
    Demetri, G
    Pisters, P
    Brennan, MF
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 818S - 818S
  • [38] A phase III randomized trial of adjuvant biochemotherapy (BC) versus interferon-α-2b (IFN) in patients (pts) with high risk for melanoma recurrence.
    Kim, K. B.
    Legha, S. S.
    Gonzalez, R.
    Anderson, C.
    Papadopoulos, N. E.
    Eton, O.
    Plager, C.
    Roe, A.
    Liu, P.
    Bedikian, A. Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 453S - 453S
  • [39] FINAL RESULTS OF PHASE II RANDOMIZED TRIAL OF AZACITIDINE VERSUS SUPPORT TREATMENT IN PATIENTS WITH LOW RISK MYELODYSPLASTIC SYNDROME WITHOUT THE 5Q DELETION
    Sanchez-Garcia, J.
    Falantes, J.
    Medina, A.
    Hernandez-Mohedo, F.
    Torres-Sabariego, A.
    Bailen, A.
    Sole, M.
    Casano, J.
    Calderon, C.
    Hermosin, L.
    Vahi, M.
    Serrano, J.
    LEUKEMIA RESEARCH, 2015, 39 : S59 - S59
  • [40] Re: High-risk Prostate Cancer Treated with Pelvic Radiotherapy and 36 Versus 18 Months of Androgen Blockade: Results of a Phase III Randomized Study [Abstract 3]
    Bolla, Michel
    EUROPEAN UROLOGY, 2013, 64 (03) : 513 - 513
12345